z-logo
Premium
Use of 13‐Valent Pneumococcal Conjugate Vaccine and 23‐Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Author(s) -
Nancy M. Bennett,
Cynthia G. Whitney,
Matt Moore,
Tamara Pilishvili,
Kathleen L. Dooling
Publication year - 2013
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.12073
Subject(s) - medicine , advisory committee , immunization , pneumococcal conjugate vaccine , pneumococcal disease , conjugate vaccine , pneumococcal polysaccharide vaccine , pneumococcal vaccine , pediatrics , immunology , streptococcus pneumoniae , microbiology and biotechnology , antigen , public administration , political science , biology , antibiotics
This document details the new recommendation for utilizing the 13‐valent pneumococcal conjugate vaccine in place of the 23‐valent polysaccharide vaccine in transplant recipients and the majority of candidates.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here